Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients newly diagnosed with BOS post HSCT and analyz...

Full description

Bibliographic Details
Main Authors: Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, Yuanyuan Shi, Lining Zhang, Mengze Hao, Fei Zhao, Rongli Zhang, Jialin Wei, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
bronchiolitis obliterans syndrome (BOS)
ruxolitinib
hematopoietic stem cell transplantation (HSCT)
cGVHD
pulmonary function test (PFT)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.916472/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.916472/full

Similar Items